CIBC Asset Management Inc Purchases 9,132 Shares of Astrazeneca Plc $AZN

CIBC Asset Management Inc lifted its position in shares of Astrazeneca Plc (NYSE:AZN) by 3.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 253,856 shares of the company’s stock after purchasing an additional 9,132 shares during the quarter. CIBC Asset Management Inc’s holdings in Astrazeneca were worth $44,552,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Lloyd Advisory Services LLC. bought a new position in shares of Astrazeneca during the fourth quarter worth $35,000. Basepoint Wealth LLC bought a new position in shares of Astrazeneca during the fourth quarter worth $44,000. Bangor Savings Bank boosted its position in shares of Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares in the last quarter. Eagle Bay Advisors LLC bought a new stake in Astrazeneca in the 4th quarter valued at $30,000. Finally, Triumph Capital Management bought a new stake in Astrazeneca in the 3rd quarter valued at $25,000. 20.35% of the stock is owned by institutional investors.

Analyst Ratings Changes

AZN has been the topic of several research reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, May 13th. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Monday. TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Finally, Weiss Ratings initiated coverage on shares of Astrazeneca in a research report on Wednesday, March 11th. They issued a “buy (b)” rating on the stock. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Stock Down 0.7%

Astrazeneca stock opened at $176.28 on Thursday. The firm has a market capitalization of $273.39 billion, a PE ratio of 26.47, a P/E/G ratio of 1.41 and a beta of 0.25. The company’s 50-day moving average is $190.88 and its 200-day moving average is $184.54. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. The company had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Sell-side analysts anticipate that Astrazeneca Plc will post 10.26 earnings per share for the current year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.